Candida auris is a multidrug-resistant fungal pathogen that presents a serious threat to
global human health. Since the first reported case in 2009 in Japan, C. auris infections have …

All serious fungal infections need appropriate antifungal therapy for successful patient
outcome. Only a few classes of antifungal drugs are available, so the emergence of …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

The epidemiology of Candida infections has changed in recent years. Although Candida
albicans is still the main cause of invasive candidiasis in most clinical settings, a substantial …

Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in the United
States. We examined data from the National Center for Health Statistics and reviewed recent …

Candida infections (candidiasis) are the most prevalent opportunistic fungal infection on
humans and, as such, a major public health problem. In recent decades, candidiasis has …

Fungal biofilm infections have become increasingly recognised as a significant clinical
problem. One of the major reasons behind this is the impact that these have upon treatment …

Candida commonly adheres to implanted medical devices, growing as a resilient biofilm
capable of withstanding extraordinarily high antifungal concentrations. As currently available …

Fungal infections due to Candida and Aspergillus species cause extensive morbidity and
mortality, especially among immunosuppressed patients, and antifungal therapy is critical to …

Pathogenic fungi have become a leading cause of human mortality due to the increasing
frequency of fungal infections in immunocompromised populations and the limited …